Oncology News | pharmaphorum

News

AI improves adenoma detection in colonoscopies

An artificial intelligence-powered computer-aided detection (CAD) system developed by Israeli medtech company Magentiq-Eye has been shown to improve detection rates for ad

News

After Roche’s exit, Blueprint passes Gavreto on to Rigel

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

News

US, EU regulators start swift reviews of Servier glioma drug

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this a

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

AI improves adenoma detection in colonoscopies

After Roche’s exit, Blueprint passes Gavreto on to Rigel

Regeneron set for August FDA decision on BCMA bispecific

US, EU regulators start swift reviews of Servier glioma drug

AZ, Daiichi eye December verdict for TROP2 ADC

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks